# GLP-1-remmers verlagen risico op levercomplicaties en chronische nierziekte bij diabetes en chronische hepatitis

*geplaatst 2026-11-04 · Nierziekte · Clinical and molecular hepatology · doi 10.3350/cmh.2026.0746 · https://hartvaat.nl/2026/10/27/glp-1-remmers-verlagen-risico-op-levercomplicaties-en-chronische-nierziekte-bij-/*

Een retrospectieve cohortstudie onder bijna 10.000 patiënten met type 2-diabetes en chronische virale hepatitis toont dat GLP-1-remmers het risico op levercomplicaties (HR 0,71), levercelcarcinoom (HR 0,53) en chronische nierziekte (HR 0,67) significant verlagen. Er werd een trend gezien naar minder cardiovasculaire ziekte en niet-leverkanker, maar deze bereikte geen statistische significantie. Deze bevindingen ondersteunen het gebruik van GLP-1-remmers bij deze complexe patiëntengroep om zowel lever- als niercomplicaties te voorkomen.

## English: GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis.

A retrospective cohort study of nearly 10,000 patients with type 2 diabetes and chronic viral hepatitis found that GLP-1 receptor agonists significantly reduced the risk of liver-related outcomes (HR 0.71), hepatocellular carcinoma (HR 0.53), and chronic kidney disease (HR 0.67). Non-significant trends were observed for reduced cardiovascular disease and non-liver cancer. These findings support the use of GLP-1 receptor agonists in this comorbid population to mitigate both hepatic and renal complications.

## Abstract (original, from the publication)

BACKGROUND/AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the effect of GLP-1RA on liver and non-liver complications among patients with T2D and CVH in the United States. METHODS: Patients with T2D and CVH initiating GLP-1RA were included (2013-2022) in Merative™ Marketscan® Research Databases. Primary outcomes included (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Cox proportional hazards models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI). RESULTS: A total of 9,499 patients with T2D and CVH were included after 1:4 propensity score matching. Compared with non-GLP-1RA (N=7,366), GLP-1RA use (N=2,133) was associated with significantly lower risks of any liver-related outcomes (HR 0.71, 95% CI 0.57-0.87; P=0.001), HCC (HR 0.53, 95% CI 0.31-0.93; P=0.028), cirrhosis (HR 0.70, 95% CI 0.56-0.86; P<0.001), CKD (HR 0.67, 95% CI 0.53-0.84; P<0.001). A trend toward a lower risk of CVD (HR 0.82, 95% CI 0.66-1.03; P=0.089) and non-liver cancer (HR 0.73, 95% CI 0.53-1.01; P=0.055) was observed among GLP-1RA users, although the association did not reach statistical significance. CONCLUSIONS: GLP-1RA use was associated with lower risks of cirrhosis, HCC, and CKD among patients with T2D and CVH, with nonsignificant trends toward lower risks of CVD and non-liver cancer.

Auteurs: Xinrong Zhang, Xianhua Mao, Scott Barnet, Ramsey Cheung, Mindie H Nguyen

---
Bron: Clinical and molecular hepatology, https://doi.org/10.3350/cmh.2026.0746. Bijgewerkt 2026-10-28T02:59:30Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.